Nicotine Replacement Therapy Prop 65 Warning Unfounded, FDA Tells Court
This article was originally published in The Tan Sheet
Executive Summary
A California appellate court's ruling that a Prop 65 warning for nicotine replacement therapies is not federally preempted would require product manufacturers to use warning language FDA has determined lacks scientific support, the agency says